Magda Marquet Biography and Net Worth

Director of AnaptysBio

Dr. Magda Marquet has built, led and commercialized multiple life science companies. She is the co-founder of AltheaDx, a commercial stage, precision medicine company with the world’s leading pharmacogenomics test for anxiety and depression, and ALMA Life Sciences, LLC, an early stage investment firm creating and growing innovative healthcare companies. Dr. Marquet co-founded Althea Technologies and, as its co-CEO with full P&L responsibility, led the company to become a leader in the field and a highly profitable, commercial company. As a result, she guided Althea to acquisition by Ajinomoto, a global Japanese company and leader in amino acid technology. Prior to starting Althea Technologies, Dr. Marquet held several positions in pharmaceutical development in companies such as Vical and Amylin Pharmaceuticals. She currently serves on the Board of Directors of Arcturus Therapeutics, Micronoma, Matrisys Biosciences and ProciseDx. Dr. Marquet holds a Ph.D in Biochemical Engineering from INSA/University of Toulouse, France. She has received numerous prestigious awards throughout her career including the 2005 Regional Ernst & Young Entrepreneur of the Year award in the Life Sciences category, the Athena Pinnacle award, the Director of the Year award (Corporate Governance) from the Corporate Directors Forum and has been inducted into the CONNECT Entrepreneur Hall of Fame.

What is Magda Marquet's net worth?: The estimated net worth of Magda Marquet is at least $493.82 thousand as of January 15th, 2026. Marquet owns 9,930 shares of AnaptysBio stock worth more than $493,819 as of February 8th. This net worth estimate does not reflect any other assets that Marquet may own. Learn More about Magda Marquet's net worth.
How do I contact Magda Marquet?: The corporate mailing address for Marquet and other AnaptysBio executives is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. AnaptysBio can also be reached via phone at (858) 362-6295 and via email at [email protected]. Learn More on Magda Marquet's contact information.
Has Magda Marquet been buying or selling shares of AnaptysBio?: In the last ninety days, Magda Marquet has sold $530,530.00 in shares of AnaptysBio stock. Most recently, Magda Marquet sold 11,000 shares of the business's stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $48.23, for a transaction totalling $530,530.00. Following the completion of the sale, the director now directly owns 9,930 shares of the company's stock, valued at $478,923.90. Learn More on Magda Marquet's trading history.
Who are AnaptysBio's active insiders?: AnaptysBio's insider roster includes Daniel Faga (President & CEO), Dennis Fenton (Director), Paul Lizzul (Chief Medical Officer), Eric Loumeau (COO), Magda Marquet (Director), Dennis Mulroy (CFO), Hollings Renton (Director), Hamza Suria (CEO), and J. Ware (Director). Learn More on AnaptysBio's active insiders.
Are insiders buying or selling shares of AnaptysBio?: In the last twelve months, insiders at the biotechnology company sold shares 22 times. They sold a total of 167,205 shares worth more than $7,208,140.88. The most recent insider tranaction occured on January, 15th when Director Magda Marquet sold 11,000 shares worth more than $530,530.00. Insiders at AnaptysBio own 33.5% of the company. Learn More about insider trades at AnaptysBio.
Information on this page was last updated on 1/15/2026.

Magda Marquet Insider Trading History at AnaptysBio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/15/2026	Sell	11,000	$48.23	$530,530.00	9,930

Magda Marquet Buying and Selling Activity at AnaptysBio

AnaptysBio Company Overview

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Today's Range

Now: $49.73

$48.57

$51.74

50 Day Range

MA: $46.86

$40.90

$51.21

2 Week Range

Now: $49.73

$12.21

$52.47

Volume

501,404 shs

Average Volume

387,621 shs

Market Capitalization

$1.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35